William E. Boden, MD

Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

I am ABIM board-certified in both Internal Medicine and the subspecialty of Cardiovascular Disease. Since 1979, I have held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and Albany Medical College. For the past 27 consecutive years, I have held leadership roles as either a Chief of cardiology or Chief of Medicine at both federal VA facilities and in the academic private sector, all of which have had strong affiliations with their respective academic health centers. In 2016, I re-joined the VA Boston MAVERIC Center as the Scientific Director, Clinical Trials Network, for the VA New England Healthcare System, and as the Research Lead Physician, for VISN 1.

I have extensive prior experience in clinical trials and comparative effectiveness research, and have served in a leadership capacity in several important national and international clinical trials, including as Study Chair for VA CSP-funded VANQWISH and COURAGE Trials, as Study Co-Chair of the NIH-funded AIM-HIGH Trial, and as a national co-PI for the NIH-funded ISCHEMIA Trial. My principal research interests include studies in stable ischemic heart disease, post-MI secondary prevention, acute coronary syndromes, and preventive cardiology.

Publications

  • Published 10/31/2026

    Lakshmanan S, Wang Y, Chen YQ, Mancini GJ, Leipsic J, Budoff M, Hague C, Min JK, Stone GW, Boden WE, Spertus JA, Bangalore S, Hochman JS, Reynolds HR, Maron DJ. Sex-Specific Coronary Plaque Characteristics and Risk of Cardiovascular Events: Insights from ISCHEMIA. Am Heart J. 2026 Oct 31; 107633. PMID: 42966435.

    Read at: PubMed

  • Published 10/5/2026

    Park DW, Boden WE, De Caterina R, Gallinoro E, Ahn JM, Bairey Merz CN, Kaski JC, Kang DY, Kaul S, Marzilli M, Pepine CJ, Park SJ, Barbato E. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. Eur Heart J. 2026 Oct 05; 47(37):5293-5305. PMID: 41790132.

    Read at: PubMed

  • Published 8/11/2026

    Grodzinsky A, Cho YJ, Jones PG, Shaw LJ, Merz CNB, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ, Hochman JS, Reynolds HR. Sex differences in coronary disease health Status outcomes: the ISCHEMIA trial. Eur Heart J Qual Care Clin Outcomes. 2026 Aug 11; 12(5):765-769. PMID: 41978343.

    Read at: PubMed

  • Published 8/5/2026

    O'Keefe EL, Saxon JT, Cho YJ, Jones PG, Mark DB, Bangalore S, Boden WE, Stone GW, Reynolds HR, Hochman JS, Maron DJ, Spertus JA. Assessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease. Circ Popul Health Outcomes. 2026 Sep; 19(9):e013063. PMID: 42554061.

    Read at: PubMed

  • Published 6/25/2026

    Manivannan A, Schou M, Boden WE, Fosbøl E, Køber L, Gislason GH, Monahan K, Torp-Pedersen C, Andersson C. Ischemic Evaluation and Long-Term Mortality in New-Onset Heart Failure Across Various Age-Groups. Int J Heart Fail. 2026 Jul; 8(3):207-215. PMID: 42568480.

    Read at: PubMed

View All 433 Publications:   View Full Profile in BUMC

Other Positions

  • Lecturer in Medicine
    Harvard Medical School
  • Physician Research Lead & Scientific Director, MAVERIC Center
    VA Boston Healthcare System

Websites

Education

  • State University of New York at Brockport, MD
  • Le Moyne College, BS

View all profiles